Illumina Inc., ILMN is in the exchange NASDAQ and its industry is Biotechnology in the sector of Healthcare. Based in USA, Illumina Inc., ILMN has a market cap of 22255.55. Since its IPO date on the 7/28/2000, Illumina Inc., ILMN performance year to date is -21.52%. Today Illumina Inc., ILMN has gained -0.09%, with a current price of 150.51.
Ownership of the company is 1.20% for insider ownership while institutional ownership is 96.80%. The management of the company have seen the company have a payout ratio of 0.00%. Return of assets are at 11.10%, with return on investment at 16.60%.
In terms of debt levels and profit levels, Illumina Inc., ILMN is seeing a long-term debt/equity of 0.51. While Total debt/equity is 0.51. With a profit margin of 18.40%, this is combined with a gross margin of 69.70%, and operating margin of 24.80%. Illumina Inc. ability to meet debt levels, with a current ratio of 4.3, while the quick ratio is 3.7.
For the last year Illumina Inc., ILMN has seen a EPS growth of 30.50%. A performance for the year of -31.87%. The 52-week high is -31.86%, and the 52-week low is 18.41%. The average volume for Illumina Inc., ILMN is 757299.
With a target price of 153.53, can Illumina Inc., ILMN reach this target? Looking at the value indicators of Illumina Inc., ILMN. Illumina Inc. has a P/E of 54.17 and a forward P/E of 37.87. Perhaps the more useful indicator than P/E, is PEG which has a value of 3.29. Illumina Inc. also has a P/S and a P/B of 9.88 and 11.11 respectively. For P/cash, Illumina Inc. has a value of 16.57, while it is 47.1 for P/free cash flow.
At the current price of 150.51, Illumina Inc. has a dividend yield of *TBA. We see a return on equity of 21.90%.
Looking more long-term Illumina Inc., is projected to get an EPS growth for the next five years of 16.45%. In the short-term an EPS growth of 17.97% in the next year is forecasted. This is after a EPS growth of 30.50% for this year and for the last five years a 28.90% growth has been seen.